Medicinal Preparations Containing Tepotinib

CzechTenders notice for Medicinal Preparations Containing Tepotinib. The reference ID of the tender is 92179554 and it is closing on 11 Dec 2023.

100% Secure Payments

Tender Details

  • Country: Czech Republic
  • Summary: Medicinal Preparations Containing Tepotinib
  • CZT Ref No: 92179554
  • Deadline: 11 Dec 2023
  • Competition: ICB
  • Financier: Self Financed
  • Purchaser Ownership: Public
  • Tender Value: 14949600
  • Notice Type: Tender
  • Document Ref. No.: 686820-2023
  • Purchaser's Detail :
  • Purchaser : HRADEC KRALOVE UNIVERSITY HOSPITAL
    Address : Sokolska 581
    Town : Hradec Kralove
    NUTS-Code : CZ052 - Hradec Kralove region
    Postal Code : 50005
    Contact Point : Benjamin Křikava
    Phone : 420 495834224
    Email :benjamin.krikava@fnhk.cz
    URL :https://www.fnhk.cz/

  • Description :
  • The subject of the public contract is the continuous supply of medicinal products containing tepotinib for a period of 4 years according to the current needs of the contracting authority.
    Doc Title: Antineoplastic agents
    Contract Type: Supplies
  • Documents :
  •  Tender Notice

If you are registered member, kindly login to view full details of this tender notice:

CLICK HERE TO LOGIN
CzechTenders Features

CzechTenders Features

Fresh and verified Tenders from Czech. Find, search and filter Tenders/Call for bids/RFIs/RFPs/RFQs/Auctions published by the government, public sector undertakings (PSUs) and private entities.

  • 1,000+ Tenders
  • Verified Tenders Only
  • Accurate Tender Information
  • New Tenders Every Day
  • Consultants for RFI/RFP/RFQ
  • Search, sort, and filter Tenders
  • Customer Support
  • Publish your Tenders
  • Consulting Services
  • Export data to Excel or CRM

Get A Call From Tender Experts

Fill out the form below and you will receive a call from us within 24 hours.

Thank You for Contacting ZimbabweTenders !!
Email Id is already exist !!
Invalid Captcha !

Get FREE SAMPLE TENDERS from Czech in your email inbox.

  Chat with us